GENE ONLINE|News &
Opinion
Blog

2017-11-06|

November 6, 1946: Celebrate the Birthday of American Genetictist Douglas C. Wallace

by GeneOnline
Share To

Douglas Cecil Wallace (November 6, 1946 – present) is an American geneticist known for his study in mitochondrial DNA. In 1975, Wallace and the other associate researchers proved for the first time that mutations on mitochondrial DNA region are related to genetic disorders. Later in 1990 he described a mitochondrial DNA mutation as the cause of a specific form of myoclonic epilepsy, and the discovery swiftly raised the attention in medicine and academia. Wallance was the first scientist to use human mitochondrial DNA as a molecular marker, and has greatly contributed to the study of the mitochondrial genome in evolution, DNA paternity testing, historical research, and genetic medicine.

Reference

https://en.wikipedia.org/wiki/Douglas_C._Wallace

Image Source

https://en.wikipedia.org/wiki/Douglas_C._Wallace

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Unveiling the Genetic Links to Dietary Preferences: A Milestone in Precision Nutrition
2023-07-26
R&D
New Mitochondrial Response Pathway May Advance Treatments for Inflammatory Diseases
2022-07-14
R&D
Massive Human CRISPR-Based Genotype-Phenotype Map Is Now Complete
2022-06-13
LATEST
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top